1. Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype
- Author
-
Canan Alhan, Arjan A. van de Loosdrecht, Dana A. Chitu, Aniek O. de Graaf, Heleen Visser-Wisselaar, Bianca Venniker-Punt, Linda Smit, Eline M. P. Cremers, Theresia M. Westers, Florentien E. M. in ’t Hout, Joop H. Jansen, Carolien Duetz, VU University medical center, Hematology laboratory, Internal medicine, CCA - Cancer biology and immunology, Hematology, AII - Cancer immunology, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), and RS: FHML non-thematic output
- Subjects
Male ,mutational analysis ,Haematological malignancy ‐ Biology ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,Mutant ,Short Report ,Splicing Factor 3B Subunit 1 ,Bone Marrow Cells ,diagnostic haematology ,Biology ,medicine.disease_cause ,Immunophenotyping ,03 medical and health sciences ,0302 clinical medicine ,Short Reports ,hemic and lymphatic diseases ,medicine ,Humans ,Myelomonocyte ,Mutation ,Myelodysplastic syndromes ,flow cytometry ,SF3B1 ,Hematology ,Phosphoproteins ,medicine.disease ,Phenotype ,myelodysplastic syndromes ,3. Good health ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer research ,Chromosomes, Human, Pair 5 ,Female ,RNA Splicing Factors ,Bone marrow ,Gene Deletion ,030215 immunology - Abstract
Summary Splicing factor 3B subunit 1 (SF3B1) mutations define a distinct myelodysplastic syndromes (MDS) patient group with a relatively favourable disease course and high response rates to luspatercept. Few data are available on bone marrow phenotype beyond ring sideroblasts in this subgroup of patients with MDS. In the present study, we identified immunophenotypic erythroid, myelomonocyte and progenitor features associated with SF3B1 mutations. In addition, we illustrate that SF3B1‐mutation type is associated with distinct immunophenotypic features, and show the impact of co‐occurrence of a SF3B1 mutation and a deletion of chromosome 5q on bone marrow immunophenotype. These genotype–phenotype associations and phenotypic subtypes within SF3B1‐MDS provide leads that may further refine prognostication and therapeutic strategies for this particular MDS subgroup.
- Published
- 2021
- Full Text
- View/download PDF